8-K: FDA Approves MYQORZO; Royalty Pharma's Revenue Stream Boosted

Royalty Pharma's investment in Cytokinetics' MYQORZO is set to generate significant royalties and repayments following FDA approval for obstructive hypertrophic cardiomyopathy.

Summary

• Cytokinetics, Incorporated announced on December 19, 2025, that the U.S. Food and Drug Administration (FDA) approved its New Drug Application for MYQORZO (aficamten).
• MYQORZO is approved for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
• Royalty Pharma is entitled to a royalty of 4.5% on MYQORZO sales up to $5 billion, which will decrease to 1% on sales above $5 billion, as per funding agreements from January 2022 and May 2024.
• Royalty Pharma provided Cytokinetics up to $225 million in long-term capital in 2022, all of which has been drawn.
• An additional $225 million in launch capital was provided in 2024, with $50 million drawn to date.
• Royalty Pharma is expected to receive $523 million in quarterly repayments over 10 years (1.9x the total amount drawn from the 2022 and 2024 funding), with $20 million already repaid through September 30, 2025.
• Following MYQORZO approval, Cytokinetics is eligible to draw an additional $175 million within the next 12 months, for which Royalty Pharma will receive 1.9x the total amount drawn, payable over 10 years in quarterly installments.

Sentiment

Score: 9

Explanation: The FDA approval of a key drug in Royalty Pharma's portfolio is a highly positive event, validating its investment strategy and securing future revenue streams and repayments.

Positives

• FDA approval of MYQORZO (aficamten) for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) significantly de-risks Royalty Pharma's investment.
• Royalty Pharma is entitled to a substantial royalty of 4.5% on MYQORZO sales up to $5 billion, providing a significant revenue stream.
• Guaranteed repayments of $523 million over 10 years from previous funding agreements, with $20 million already received through September 30, 2025.
• Potential for an additional $175 million to be drawn by Cytokinetics, leading to further repayments for Royalty Pharma at a 1.9x multiple.

Risks

• Forward-looking statements are not a guarantee of performance and are subject to many risks, uncertainties, and other variable circumstances.
• Actual results could differ materially from those anticipated due to factors outside the company's control.
• Reliance on third-party data and internal estimates, which have not been independently verified and may have limitations regarding accuracy or reliability.
• The company does not undertake to update forward-looking statements except as required by law.

Future Outlook

Following FDA approval, Cytokinetics is eligible to draw an additional $175 million within the next 12 months, which will result in Royalty Pharma receiving 1.9x the drawn amount in quarterly installments over 10 years. This indicates a continued revenue stream and potential for further investment returns for Royalty Pharma.

Industry Context

The FDA approval of MYQORZO for obstructive hypertrophic cardiomyopathy addresses a significant unmet medical need in a specific cardiovascular disease area. This approval strengthens the pipeline for companies involved in cardiac therapies and validates the investment model of royalty companies like Royalty Pharma, which provide capital in exchange for future sales participation. It introduces a new competitor in the oHCM market, which includes existing therapies such as Bristol Myers Squibb's Camzyos (mavacamten).

Comparison to Industry Standards

• The 4.5% royalty rate on initial sales up to $5 billion, decreasing to 1% thereafter, is within the typical range for pharmaceutical royalty agreements, which vary based on drug development stage, market potential, and negotiation leverage.
• The 1.9x repayment multiple on capital provided represents a strong return profile for financing drug development and launch, reflecting the inherent risks and potential rewards in the biotech sector.
• MYQORZO's approval positions it to compete in the hypertrophic cardiomyopathy market, alongside therapies like Bristol Myers Squibb's Camzyos (mavacamten), approved in 2022, offering an alternative treatment option and expanding the market.

Stakeholder Impact

• Shareholders (Royalty Pharma): Positive impact due to secured future revenue streams, de-risked investment, and potential for increased earnings.
• Shareholders (Cytokinetics): Highly positive due to FDA approval, enabling market launch and revenue generation for their drug.
• Patients with oHCM: Positive impact as a new treatment option (MYQORZO) becomes available to improve functional capacity and symptoms.

Next Steps

• Cytokinetics will proceed with the commercial launch of MYQORZO.
• Royalty Pharma will begin receiving royalties on MYQORZO sales.
• Royalty Pharma will continue to receive quarterly repayments on previously drawn capital.
• Cytokinetics may draw an additional $175 million from Royalty Pharma within the next 12 months, triggering further repayments.

Key Dates

Recommendation

The FDA approval of MYQORZO is a significant positive catalyst for Royalty Pharma, validating its substantial investment and securing long-term royalty and repayment streams. This de-risks a major asset and provides clear visibility into future cash flows, making the stock highly attractive for investors seeking exposure to successful drug commercialization without direct R&D risk.

Keywords

Royalty Pharma, RPRX, Cytokinetics, MYQORZO, aficamten, FDA approval, hypertrophic cardiomyopathy, oHCM, cardiac myosin inhibitor, royalties, pharmaceutical, biotech, drug approval, 8-K